This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hou, D.-Y. Articles by Munn, D. H. Search for Related Content PubMed PubMed Citation Articles by Hou, D.-Y. Articles by Munn, D. H.

Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses

¹ Immunotherapy Center and Departments of ² Pediatrics, ³ Medicine, and ⁴ Biostatistics, Medical College of Georgia, Augusta, Georgia; ⁵ Lankenau Institute for Medical Research, Wynnewood, Pennsylvania; ⁶ NewLink Genetics Corporation, Ames, Iowa; and ⁷ Department of Pathology, Anatomy, and Cell Biology, Jefferson Medical College, Philadelphia, Pennsylvania

Requests for reprints: David H. Munn, Immunotherapy Center, Medical College of Georgia, CN-4141, Augusta, GA 30912. Phone: 706-721-7141; Fax: 706-721-8732; E-mail: dmunn{at}mcg.edu or George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA 19096. E-mail: prendergastgt{at}limr.org.

Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that contributes to tolerance in a number of biological settings. In cancer, IDO activity may help promote acquired tolerance to tumor antigens. The IDO inhibitor 1-methyl-tryptophan is being developed for clinical trials. However, 1-methyl-tryptophan exists in two stereoisomers with potentially different biological properties, and it has been unclear which isomer might be preferable for initial development. In this study, we provide evidence that the D and L stereoisomers exhibit important cell type–specific variations in activity. The L isomer was the more potent inhibitor of IDO activity using the purified enzyme and in HeLa cell–based assays. However, the D isomer was significantly more effective in reversing the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte–derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes. In vivo, the D isomer was more efficacious as an anticancer agent in chemo-immunotherapy regimens using cyclophosphamide, paclitaxel, or gemcitabine, when tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer. The D isomer of 1-methyl-tryptophan specifically targeted the IDO gene because the antitumor effect of D-1-methyl-tryptophan was completely lost in mice with a disruption of the IDO gene (IDO-knockout mice). Taken together, our findings support the suitability of D-1-methyl-tryptophan for human trials aiming to assess the utility of IDO inhibition to block host-mediated immunosuppression and enhance antitumor immunity in the setting of combined chemo-immunotherapy regimens. [Cancer Res 2007;67(2):792–801]

This article has been cited by other articles:

				F. Qian, J. Villella, P. K. Wallace, P. Mhawech-Fauceglia, J. D. Tario Jr., C. Andrews, J. Matsuzaki, D. Valmori, M. Ayyoub, P. J. Frederick, et al. Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer Cancer Res., July 1, 2009; 69(13): 5498 - 5504. [Abstract] [Full Text] [PDF]

				Y. Liu, Y. Peng, M. Mi, J. Guevara-Patino, D. H. Munn, N. Fu, and Y. He Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice J. Immunol., May 15, 2009; 182(10): 5960 - 5969. [Abstract] [Full Text] [PDF]

				J. Zeng, S. Cai, Y. Yi, Y. He, Z. Wang, G. Jiang, X. Li, and J. Du Prevention of Spontaneous Tumor Development in a ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan Cancer Res., May 1, 2009; 69(9): 3963 - 3970. [Abstract] [Full Text] [PDF]

				A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology Blood, March 12, 2009; 113(11): 2394 - 2401. [Abstract] [Full Text] [PDF]

				J. C. O'Connor, M. A. Lawson, C. Andre, E. M. Briley, S. S. Szegedi, J. Lestage, N. Castanon, M. Herkenham, R. Dantzer, and K. W. Kelley Induction of IDO by Bacille Calmette-Guerin Is Responsible for Development of Murine Depressive-Like Behavior J. Immunol., March 1, 2009; 182(5): 3202 - 3212. [Abstract] [Full Text] [PDF]

				Y.-I. Jeong, S. W. Kim, I. D. Jung, J. S. Lee, J. H. Chang, C.-M. Lee, S. H. Chun, M.-S. Yoon, G. T. Kim, S. W. Ryu, et al. Curcumin Suppresses the Induction of Indoleamine 2,3-Dioxygenase by Blocking the Janus-activated Kinase-Protein Kinase C{delta}-STAT1 Signaling Pathway in Interferon-{gamma}-stimulated Murine Dendritic Cells J. Biol. Chem., February 6, 2009; 284(6): 3700 - 3708. [Abstract] [Full Text] [PDF]

				M.-C. Yen, C.-C. Lin, Y.-L. Chen, S.-S. Huang, H.-J. Yang, C.-P. Chang, H.-Y. Lei, and M.-D. Lai A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA Clin. Cancer Res., January 15, 2009; 15(2): 641 - 649. [Abstract] [Full Text] [PDF]

				M. E.D. Chamuleau, A. A. van de Loosdrecht, C. J. Hess, J. J.W.M. Janssen, A. Zevenbergen, R. Delwel, P. J.M. Valk, B. Lowenberg, and G. J. Ossenkoppele High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome Haematologica, December 1, 2008; 93(12): 1894 - 1898. [Abstract] [Full Text] [PDF]

				N. Yoshida, K. Ino, Y. Ishida, H. Kajiyama, E. Yamamoto, K. Shibata, M. Terauchi, A. Nawa, H. Akimoto, O. Takikawa, et al. Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model Clin. Cancer Res., November 15, 2008; 14(22): 7251 - 7259. [Abstract] [Full Text] [PDF]

				A. J. Muller, M. D. Sharma, P. R. Chandler, J. B. DuHadaway, M. E. Everhart, B. A. Johnson III, D. J. Kahler, J. Pihkala, A. P. Soler, D. H. Munn, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase PNAS, November 4, 2008; 105(44): 17073 - 17078. [Abstract] [Full Text] [PDF]

				O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]

				K. Ino, E. Yamamoto, K. Shibata, H. Kajiyama, N. Yoshida, M. Terauchi, A. Nawa, T. Nagasaka, O. Takikawa, and F. Kikkawa Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival Clin. Cancer Res., April 15, 2008; 14(8): 2310 - 2317. [Abstract] [Full Text] [PDF]

				S. Lob, A. Konigsrainer, R. Schafer, H.-G. Rammensee, G. Opelz, and P. Terness Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells Blood, February 15, 2008; 111(4): 2152 - 2154. [Abstract] [Full Text] [PDF]

				T. F. Gajewski, E. A. Grimm, B. J. Nickoloff, and A. T. Weeraratna New Potential Therapeutic Targets in Melanoma ASCO Educational Book, January 1, 2008; 2008(1): 404 - 407. [Abstract] [Full Text] [PDF]

				R. Riesenberg, C. Weiler, O. Spring, M. Eder, A. Buchner, T. Popp, M. Castro, R. Kammerer, O. Takikawa, R. A. Hatz, et al. Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma Clin. Cancer Res., December 1, 2007; 13(23): 6993 - 7002. [Abstract] [Full Text] [PDF]

				T. F. Gajewski Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261. [Abstract] [Full Text] [PDF]

				R. Metz, J. B. DuHadaway, U. Kamasani, L. Laury-Kleintop, A. J. Muller, and G. C. Prendergast Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound D-1-Methyl-Tryptophan Cancer Res., August 1, 2007; 67(15): 7082 - 7087. [Abstract] [Full Text] [PDF]